mIL-21基因治疗小鼠肿瘤及其机制的初步研究

建立小鼠Sp2/0皮下肿瘤模型,以我们构建并鉴定过的真核表达质粒peDNA3.1/mIL-21在瘤体内直接注射,考察mIL-21基因治疗对小鼠Sp2/0肿瘤的疗效。结果显示pcDNA3.1/mIL-21质粒治疗对小鼠皮下Sp2/0肿瘤有一定的生长抑制作用,CTL和NK细胞毒活性明显增强,IFN-γ分泌升高显著,但抗体无明显升高。表明mIL-21基因治疗的抗肿瘤效应,可能和细胞免疫功能增强有关。     

小鼠白细胞介素21 cDNA的克隆及真核表达质粒的构建

目的：克隆小鼠自细胞介素2l(IL-21)基因，构建真核表达质粒，用以进行肿瘤的基因治疗。方法：用RT-PCR法。从ConA活化的小鼠T细胞中扩增IL-21 cDNA。克隆人哺乳动物细胞高效表达质粒pcDNA3．1中，构建重组mIL-21真核表达质粒。重组体用载体上的通用引物和PCR下游引物为测序引物，鉴定克隆的正确性。将已鉴定的重组质粒用脂质体法转染Sp2／0细胞，用RT-PCR法鉴定转染细胞中IL-21基因的表达，用MTT比色法检测表达的mIL-21诱导的NK细胞杀伤活性的增强。结果：正确构建了重组真核表达质粒pcDNA3．1／mIL-21，并在转染的细胞中检测出IL-2l的表达，表达的mIL-21可在体外增强NK细胞的杀伤活性：结论：成功地构建了重组真核表达质粒pcDNA3．1／mIL-21，为进一步在肿瘤动物模型中进行IL-21基因治疗及疗效观察奠定了基础.     

Expression, purification and identification of recombinant mouse interleukin 21 protein in E. coli

Interleukin 21 （IL-21） is a novel type I cytokine that is significantly homologous to IL-2, IL-4 and IL-15. Its receptor complex contains γc chain which is also a component of receptors for IL-2, IL-4, IL-7, IL-9 and IL-15, so there may be overlapping or relevancies in their biological functions. IL-21 is capable of co-stimulating mature T cells, B cells, NK cells, and of stimulating CD16 expression on the surface of NK cells to induce ADCC in innate immune response. It can also strengthen the anti-tumor effect of the cellular immunity, especially v/a enhancing the activities of NK and antigen specific CTL cells. Thus, IL-21 is a potential useful therapeutic molecule for immunotherapy of malignancies, by eliciting innate and adaptive anti-tumor immune responses in tumor-bearing hosts. In order to study the biological functions of IL-21, we constructed a mIL-21 prokaryotic expression plasmid and expressed the recombinant mIL-21 protein in E. coli in present study. The recombinant plasmid pET28a/mIL-21 with a carboxyl terminal His-tag was subcloned from the pcDNA3.1/mIL-21 and expressed in E. coli. The induced protein was detected by SDS-PAGE, and identified by Western-blot assay with anti-mIL-21 antibody. The recombinant protein was purified v/a Ni^＋ affinity chromatography, and renatured with GSH/GSSG system. Our mouse T cell proliferation experiment showed that the recombinant mIL-21 protein could enhance the mouse T cell proliferation either by itself alone or in the presence of Con A.     

糖基化磷脂酰肌醇修饰的小鼠IL-21瘤苗抗肿瘤效应及其机制初探

目的 构建糖基化磷脂酰肌醇(glycosyl phosphafidylinositol,GPI)修饰的小鼠IL-21瘤苗,并对此瘤苗的抗肿瘤效应及其机制作初步探讨.方法 通过重叠PCR方法获得IL-21-GPI融合基因并将其插入空载体pcDNA3.1.将鉴定过的重组载体以脂质体法转染B16F10细胞制成瘤苗,细胞间接免疫荧光法及流式细胞仪检测转染瘤细胞膜表面IL-21的表达,通过对小鼠脾细胞的增殖作用鉴定表达的IL-21的生物学活性.将瘤苗接种小鼠后,通过观察小鼠肿瘤体积和生存率分析瘤苗的抗瘤性,并检测了瘤苗免疫鼠的细胞免疫活性.结果 正确构建了pcDNA3.1/IL-21-GPI重组载体,膜表达的IL-21有良好的生物学活性,制备的瘤苗能发挥抗肿瘤效应,其机制与免疫鼠细胞免疫活性增强有关.结论 成功构建了具有抗肿瘤活性的GPI修饰的IL-21瘤苗,为其进一步抗肿瘤免疫治疗研究奠定了基础.     

小鼠IFN-γ真核表达载体的构建及其抗肿瘤效应研究

目的：构建小鼠IFN-γ的真核表达载体，将载体在体外转染小鼠腹腔MΦ，观察MΦ的抗肿瘤效应。在荷瘤小鼠腹腔内注射重组表达载体，观察抗肿瘤效应。 方法： RT-PCR扩增小鼠IFN-γ mRNA，将扩增的cDNA通过亚克隆重组到表达载体pcDNA3.1上。体外转染小鼠的腹腔MΦ，RT-PCR检测小鼠IFN-γ mRNA的表达，用转染的MΦ的培养上清培养另一组MΦ，MTT法检测MΦ对肿瘤细胞的杀伤活性。将重组质粒注射到荷瘤小鼠腹腔，观察小鼠腹水出现时间和存活时间。 结果: 将小鼠基因的开放阅读框（ORF）重组到真核表达载体pcDNA3.1内，测序证实和GenBank所公布序列相符。体外将IFN-γ基因导入MΦ内并表达，其培养上清对MΦ有激活作用，杀伤肿瘤细胞活性增强。腹腔内注射重组表达载体，荷瘤小鼠的腹水增长延迟、荷瘤生存时间延长。 结论： 构建的小鼠pcDNA3.1-IFN-γ表达载体体外转染腹腔MΦ并获表达，体内外实验显示有抗肿瘤细胞活性。     

Investigation of GM-CSF immune accessory effects in tumor-bearing mice by direct gene immunization

To assess GM-CSF immune accessory effects in tumor-bearing mice, an animal tumor model was established by inoculating SP2/0 myeloma cells s.c. into the flank of Balb/c mice and 14 days later, injecting either 400 mug recombinant pcDNA3.1/mGM-CSF or a blank plasmid s.c. or i.m. into the tumor four times. The tumor weight, the activities of CTL and NK, the serum levels of IFN-gamma, IL-2 and lymphocytes infiltrating in tumor tissue were analysed 8 weeks later with MTT, ELISA and pathological section methods. The results showed that the tumor lump was reduced in mice injected s.c. (0.880 +/- 0.405 g) or i.m. (0.378 +/- 0.411 g) with pcDNA3.1/mGM-CSF compared with control mice injected s.c. (1.548 +/- 0.221g, P < 0.01)or i.m. (1.554 +/- 0.249g, P < 0.001) with a blank vector. Lymphocyte infiltration in tumor tissues was very apparent in mice injected i.m. with pcDNA3.1/mGM-CSF. In contrast, there was no lymphocyte infiltration in tumor tissues of control mice. In addition, the serum concentrations of IFN-gamma, IL-2 and the activities of CTL and NK cells were significantly increased in mice injected with pcDNA3.1/mGM-CSF compared with a control mice (P < 0.01). In conclusion, direct gene immunization of recombinant pcDNA3.1/mGM-CSF is a feasible strategy for tumor therapy.     

IL-17体内外抗肿瘤作用及其机制研究

目的研究IL-17体内外抗肿瘤作用及其机制,为IL-17基因疫苗进入临床提供实验依据。方法建立稳定转染小鼠IL-17全长基因的小鼠乳腺癌细胞(4T1/IL-17)及相应的对照细胞(4T1/pcDNA3.1、4T1),MTS法检测3种细胞的体外增殖情况;流式法检测3种细胞表面MHCI、MHCⅡ、LFA-1分子表达的变化及3种细胞的凋亡情况。建立荷瘤动物模型,观察3种细胞移植瘤在小鼠体内成瘤性、生长情况及小鼠生存期的变化。接种肿瘤细胞6周后分别检测3组小鼠脾细胞CTL杀伤活性、脾细胞增殖情况。用ELISA法检测小鼠脾细胞经刺激后产生IFN-γ、IL-12的情况;流式细胞技术检测4T1/IL-17细胞接种于小鼠体内的细胞凋亡情况及肿瘤组织细胞表面MHCI、MHCⅡ、LFA-1等分子表达的变化。结果转染IL-17基因后在体外对4T1/IL-17、4T1/pcDNA3.1和4T1细胞的增殖;MHCI、MHCⅡ、LFA-1分子表达;细胞凋亡无影响。将4T1/IL-17细胞接种小鼠体内后,荷瘤小鼠的肿瘤生长速度、体积均明显小于4T1/pcDNA3.1细胞组及4T1细胞组,生存时间也明显延长(P<0.05);肿瘤细胞凋亡率明显增高(P<0.05);细胞表面MHCI、MHCⅡ、LFA-1分子表达水平显著性增高(P<0.01);CTL杀伤活性及对ConA刺激的细胞增殖反应性均明显升高(P<0.01);可产生高水平的IFN-γ、IL-12,有显著性差异(P<0.01)。结论 IL-17在体外未显示抗肿瘤作用,IL-17在小鼠体内具有明显的抗肿瘤作用,其抗肿瘤作用与促进肿瘤细胞细胞凋亡及增强机体免疫应答有关。     

pcDNA3.1/hIL-18真核表达载体的构建及表达

目的 :构建重组真核表达质粒pcDNA3.1/IL 18,并在哺乳动物细胞COS 7和Rlc310中进行瞬时和稳定性表达。方法 :从含hIL 18基因的中介载体 pGEM TEasy( pGEM T/hIL 18)中 ,以限制性内切酶酶切方法获得目的片段 ,克隆入真核表达质粒 pcDNA3.1( )中。以脂质体法转染COS 7和Rlc310细胞 ,用RT PCR检测IL 18mRNA的水平 ,免疫组化染色法检测蛋白表达。结果 :构建了hIL 18基因的重组真核表达质粒pcDNA3.1/IL 18,并可在哺乳动物细胞中瞬时、稳定表达 ,获得了可稳定表达hIL 18基因的Rlc310细胞株。结论 :pcDNA3.1/IL 18的构建及表达 ,为IL 18抗肿瘤作用的研究奠定了基础     

Effects of tumour necrosis factor-alpha (TNF-alpha), IL-1 beta and monocytes on lymphokine-activated killer (LAK) induction from natural killer (NK) cells and T lymphocytes.

Roles of monocytes and cytokines were investigated on LAK induction from T and NK cells. Monocytes augmented more T-LAK induction than did NK-LAK. Expression of IL-1 beta, TNF-alpha and interferon-gamma (IFN-gamma)-mRNA and their cytokine production were superior in NK cells compared with T cells in parallel with their LAK activities. An increase of TNF-alpha, IL-1 beta and IFN-gamma production was induced by co-culturing NK or T cells with autologous monocytes. The augmentation of T cell cytokine production and T-LAK activity by monocytes was more prominent than that of NK cells. TNF-alpha and IL-1 beta were generated 24 h after IL-2 stimulation, and these cytokines were able to almost substitute for monocytes in LAK induction. Conversely, LAK induction was almost completely suppressed by both anti-IL-1 beta and anti-TNF-alpha antibodies, if they were added within 24 h after the start of the LAK induction. IFN-gamma, which was produced at a later stage, scarcely affected LAK induction in spite of the cooperation with TNF-alpha. The results obtained indicate conclusively that the superiority of NK-LAK depends on their superior productivity of both IL-1 beta and TNF-alpha, and that the up-regulation of LAK induction by monocytes is largely due to the enhanced generation of both cytokines.     

The construction of a new oncolytic herpes simplex virus expressing murine interleukin-15 with gene-editing technology

The treatment of tumors with oncolytic viruses is an important cancer immunotherapy strategy. Interleukin-15 (IL-15) can enhance the antitumor effect of natural killer cells and T cells. An oncolytic herpes simplex type II virus (oHSV2-mIL-15CherryFP) expressing mouse IL-15 was constructed using the CRISPR/Cas9 system, and its antitumor activity in vitro and in vivo was evaluated. In vitro, the mouse interleukin-15 (mIL-15) present in the culture supernatant expressed by oHSV2-mIL-15CherryFP was able to enhance the killing of CT26-GFP tumor cells by T cells. In addition, the intratumoral injection of oHSV2-mIL-15CherryFP inhibited tumor growth in the CT26-iRFP and BGC823-iRFP model. These results indicate that the use of oncolytic herpes simplex virus expressing IL-15 may be a potential therapeutic strategy in tumor immunotherapy.     

Differential effects of IL-4 and IL-10 on IL-2-induced IFN-gamma synthesis and lymphokine-activated killer activity.

Culture of human peripheral blood mononuclear cells (PBMC) with IL-2 stimulates synthesis of cytokines and generation of lymphokine-activated killer (LAK) activity. Both IL-4 and IL-10 [cytokine synthesis inhibitory factor (CSIF)] inhibit IL-2-induced synthesis of IFN-gamma and tumor necrosis factor (TNF)-alpha by human PBMC. However, unlike IL-4, IL-10 inhibits neither IL-2-induced proliferation of PBMC and fresh natural killer (NK) cells, nor IL-2-induced LAK activity. Moreover, IL-4 inhibits IL-2-induced IFN-gamma synthesis by purified fresh NK cells, while in contrast the inhibitory effect of IL-10 is mediated by CD14+ cells (monocytes/macrophages). IL-10 inhibits TNF-alpha synthesis by monocytes or monocytes plus NK cells, but not by NK cells alone. These results suggest that IL-4 and IL-10 act on NK cells via distinct pathways, and that IL-2-induced cytokine synthesis and LAK activity are regulated via different mechanisms.     

Antitumor activity and immune enhancement of murine interleukin-23 expressed in murine colon carcinoma cells

Interleukin （IL）-23, a cytokine composed of p19 and the p40 subunit of IL-12, can enhance the proliferation of memory T cells and production of IFN-γ from activated T cells. It can also induce antitumor effects in murine model. To further evaluate the antitumor activity and immune enhancement of IL-23 in vivo, murine colon carcinoma cells retrovirally transduced with mIL-23 gene were injected subcutaneously （s.c.） into BALB/c mice. Survival time and tumor volume were observed. LDH release assay, [^3H]-TdR incorporation assay and ELISA were used to determine CTL activity, proliferation of splenocytes and level of cytokines, respectively. Number of dendritic cells （DCs） was analyzed by flow cytometry （FCM）. IL-23 secreted by Colon26/IL-23 cells suppressed the growth of tumor and prolonged the survival time of mice, enhanced proliferation of splenocytes, CTL activity, and number of DCs. IL-23 also promoted the production of Thl cytokines such as IFN-γ, IL-12 and TNF-α. However, the level of IL-4 was not enhanced significantly. These data suggested that IL-23 secreted by tumor cells can induce antitumor activitv bv enhancing immune resnonse.     

小鼠肿瘤/睾丸抗原Biot2对NIH3T3细胞增殖的影响

目的:研究新发现的小鼠肿瘤/睾丸抗原Biot2对小鼠NIH3T3细胞生物学行为的影响,探讨基因的生物学功能。方法:构建真核表达质粒pcDNA3.1( )-Biot2,由脂质体包裹稳定转染NIH3T3细胞,用Realtime RT-PCR、Western blot等方法筛选和鉴定Biot2表达阳性细胞克隆,研究其与细胞增殖相关的生物学特征的变化。结果:成功构建真核表达重组质粒pcDNA3.1( )-Biot2,并稳定转染于NIH3T3细胞。与对照组相比,转染了Biot2cDNA的NIH3T3细胞生长速率明显增快。结论:成功地建立稳定转染小鼠新基因Biot2的NIH3T3细胞克隆;Biot2基因能影响细胞增殖的调节,促进NIH3T3细胞的增殖,为进一步研究基因生物学功能奠定了基础。     

OAZI-1增强小鼠Melan-A疫苗免疫原性

目的探讨鸟氨酸脱羧酶抗酶抑制剂-1(OAZI-1)能否增强Melan-A疫苗的免疫原性,进而诱导实验动物体内更强的细胞免疫效应。方法构建真核表达质粒pc DNA3.1(-)/OAZI-1、pc DNA3.1(-)/Melan-A及pc DNA3.1(-)/Melan-A-OAZI-1。将真核表达质粒作为基因疫苗免疫BALB/c小鼠,收集小鼠脾脏淋巴细胞及血液,用流式细胞计量术检测淋巴细胞亚群的变化;用乳酸脱氢酶(LDH)释放分析法检测脾淋巴细胞的肿瘤杀伤活性;用ELISA分析法检测血清INF-γ水平。结果成功构建了真核表达质粒pc DNA3.1(-)/OAZI-1、pc DNA3.1(-)/Melan-A及pc DNA3.1(-)/Melan-A-OAZI-1;将真核表达质粒作为基因疫苗免疫小鼠后,小鼠脾脏CD4+T细胞比率显著性升高(P0.05),其中以pc DNA3.1(-)/Melan-A-OAZI-1免疫组和pc DNA3.1(-)/Melan-A免疫组升高更为明显(二者之间无显著性差异);上述3种基因疫苗接种小鼠后,CD8+T细胞比率也显著性升高(p0.05),但以pc DNA3.1(-)/Melan-A-OAZI-1免疫组升高最为显著,与所有其他组相比均有显著性差异(P0.05);用pc DNA3.1(-)/Melan-A-OAZI-1免疫小鼠能显著增加脾淋巴细胞的肿瘤杀伤活性(P0.05);上述3种基因疫苗免疫小鼠后,仅pc DNA3.1(-)/Melan-A-OAZI-1组小鼠血清中INF-γ含量显著性升高(P0.01)。结论 OAZI-1能通过促进肿瘤抗原提呈,增加机体的抗肿瘤免疫能力。     

Cpn0308真核表达载体的构建及对小鼠免疫功能的影响

目的:构建Cpn0308重组质粒pcDNA3.1/His A-Cpn0308,将重组质粒腹腔注射小鼠后观察小鼠免疫反应变化,以期为进一步研究Cpn0308免疫保护性奠定基础。方法:构建pcDNA3.1/His A-Cpn0308,并用菌落PCR、双酶切、序列测定等多种技术确定其正确性;将重组质粒转染HeLa细胞,间接免疫荧光法检测细胞内蛋白表达情况;重组质粒免疫BALB/c小鼠,一定时间后Western blot检测血清Cpn0308抗体特异性,间接ELISA法检测小鼠血清中Cpn0308 IgG抗体水平、ELISA试剂盒检测血清中细胞因子。结果:pcDNA3.1/His A-Cpn0308重组质粒构建成功且序列正确;重组质粒转染的HeLa细胞胞浆观察到黄绿色荧光,对照组无荧光;重组质粒组血清抗体A450x±s为0.343±0.024,pcDNA3.1/His A质粒组为0.174±0.018,PBS组为0.156±0.023,WB结果显示重组质粒组小鼠血清稀释800倍后仍有特异性目的条带出现,对照组不出现;重组质粒组小鼠IFN-γ浓度均值为264 ng/L,IL-4浓度均值为22 ng/L,pcDNA3.1/His A质粒组为:IFN-γ120 ng/L,IL-4 10 ng/L,PBS组为:IFN-γ99 ng/L,IL-4 9 ng/L。重组质粒组IgG抗体水平和细胞因子水平明显升高,与对照组相比有统计学差异。结论:pcDNA3.1/His A-Cpn0308真核表达重组质粒构建成功,且能够在真核细胞中表达目的蛋白;重组质粒对小鼠进行免疫后,提高了小鼠血清IgG抗体水平和细胞因子水平,为进一步研究Cpn DNA疫苗以及研究该蛋白的生物学功能提供实验基础。     

阳离子脂质体介导IL-15基因治疗小鼠肺转移模型的实验研究

目的:用阳离子脂质体(CL)包裹pcDNA3.1-IL15制备阳离子脂质体质粒DNA复合物CL-IL15,观察其抗小鼠B16-F10肺转移瘤的治疗作用,并初步探讨其作用机制。方法:构建hIL-15真核表达载体,测定脂质体-质粒DNA复合物的最佳包封率;将该复合物转染CHO-K1细胞株,West-ern blott检测体外转染条件下IL-15蛋白的表达情况,MTT法检测细胞转染上清对CTLL-2细胞株的增殖刺激作用;建立B16-F10小鼠黑色素瘤肺转移模型,尾静脉给药,每隔1 d给药1次,共6次,治疗结束24 h后观察各组肿瘤肺转移情况;LDH释放法(乳酸脱氢酶释放法)检测脾淋巴细胞的杀伤作用,冰冻切片免疫荧光法观察NK细胞对肿瘤组织的浸润。结果:成功构建hIL-15表达载体,并验证其与阳离子脂质体的质量比为1∶5时,包裹后形成的复合物具有较好的包封率;可以在体外有效转染并表达具生物活性的分泌型IL-15蛋白;CL-IL15复合物治疗小鼠肿瘤肺转移模型,可以显著减少肿瘤肺转移结节数目,提高脾细胞对肿瘤细胞杀伤活性(P<0.05),增加NK细胞在肿瘤组织中的浸润比例。结论:阳离子脂质体质粒DNA复合物CL-IL15可有效地抑制小鼠B16-F10肺转移瘤,其作用机制可能与IL-15诱导脾细胞对肿瘤细胞的杀伤、激活NK(natural killer)细胞对肿瘤组织的浸润等机制有关。     

乙型肝炎病毒多表位抗原基因真核表达载体的构建及其在哺乳动物细胞中的表达

将自行设计、合成的乙型肝炎病毒多表位抗原基因BPT ,克隆入真核表达载体pCDNA3 1,构建重组质粒pCDNA3 1/BPT。后者经脂质体法转染小鼠BALB/c 3T3细胞 ,G4 18加压筛选出阳性转染细胞 ,并用间接免疫荧光法鉴定其在小鼠BALB/c 3T3细胞的表达。该重组质粒经胫骨前肌注射小鼠 ,10 0 μg/次每只小鼠 ,间隔 2周加强一次 ,共 3次。免疫诱发了特异性抗体和淋巴细胞增殖反应 ,并用PCR法在小鼠的心脏、肝脏及肺组织中检测到pCDNA3 1/BPT ,这为研究HBV多表达抗原的核酸疫苗提供了初步的资料     

Interleukin-12 gene modification exerts anti-tumor effects on murine mammary sarcoma cell line in vivo

The aim of this project was to investigate the anti-tumor effect of an IL-12 gene modified mammary sarcoma murine cell line, EMT6/IL-12, in mouse model. In this study, we transfected the recombinant eukaryotic plasmid encoding IL-12 gene （pcDNA6-p70） into EMT6 and obtained the IL-12 expressing EMT6/IL-12 cell line. Then EMT6/IL-12 cells were s.c. inoculated into mice. The recombinant vector treatment group was set as control. We then evaluated the inhibition of tumor growth and the anti-tumor immunity function in vivo such as cytotoxicity, proliferation of splenocytes and serial IFN-T level. And the percentage of IFN-T producing CD4 or CD8 T cells among splenocytes was also analyzed in tumor bearing mice. Our results showed that the growth of tumors was obviously inhibited in EMT6/IL-12 group. Moreover, the capacities of anti-tumor immunity were all significantly higher in EMT6/IL-12 group compared to the controls. The results of the present investigation support the notion that EMT6/IL-12 could exert gene therapy in tumor model by improving the anti-tumor cellular immunity.     

pcDNA3.1+/MAGE-3 DNA疫苗诱导特异性抗肿瘤免疫应答的实验研究

目的：构建pcDNA3.1+/MAGE-3 DNA疫苗，观察其在小鼠体内诱导特异性抗肿瘤免疫应答的能力。方法： 通过RT-PCR构建重组表达质粒pcDNA3.1+/MAGE-3；以pcDNA3.1+/MAGE-3 DNA疫苗免疫已接种肿瘤细胞的小鼠，每10 d重复免疫1次，共3次，以pcDNA3.1+、PBS为对照。末次免疫后5 d检测血清中MAGE-3抗体滴度、小鼠脾淋巴细胞的细胞毒T细胞（cytotoxic T lymphocytes，CTL）杀伤活性、细胞因子IL-2和IFN-γ的浓度，同时计算抑瘤率。结果： 成功构建了pcDNA3.1+/MAGE-3 DNA疫苗，用此疫苗免疫已接种B16/MAGE-3细胞的小鼠后，能诱导小鼠脾淋巴细胞MAGE-3特异性的杀伤活性，脾细胞培养上清中细胞因子IL-2和IFN-γ的浓度明显增高，血清中抗MAGE-3抗体在1∶20滴度时阳性，肿瘤生长被显著抑制，与pcDNA3.1+组、PBS组相比，差异显著（P＜0.01）。结论： 成功构建了pcDNA3.1+/MAGE-3 DNA疫苗，该疫苗在小鼠体内既能激活CTL杀伤活性和CD4+ T细胞活性，又能激活体液免疫反应，从而诱导出特异性的抗肿瘤免疫应答。